The generic drug Sofosbuvir for treating chronic Hepatitis C in India is soon to be launched under the brand name 'Hepcvir'.
"Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C which reduce the need for injectables," Cipla Chief Medical Officer Jaideep Gogtay said.
Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available to Indian patients in a week's time.
"Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations," Cipla MD & Global CEO Subhanu Saxena said.
Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.